The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...

Shares of Eli Lilly (NYSE: LLY), the pharmaceuticals giant and maker of the Mounjaro and Zepbound weight loss drugs, saw its ...

The two main players in the global obesity market are Eli Lilly LLY and Novo Nordisk NVO, with their respective GLP-1 ...

Zepbound approved for treating moderate to severe obstructive sleep apnea in adults with obesity, showing improvement in ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

Chinese drugmakers are racing to roll out cheaper or more innovative alternatives. Read more at straitstimes.com. Read more ...

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...